4 completed, 4 unknown, 1 not yet recruiting, 1 recruiting. 5 Phase 2, 3 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 3, Completed 2 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Cisplatin Adverse Reaction: new trials by email Literature Review of Cisplatin Adverse Reaction trials Research Report on Cisplatin Adverse Reaction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of GMDTC Injection in Participants With Solid Tumors and Cisplatin-Induced Renal Dysfunction GMDTC 1 mg/ml, GMDTC 2mg/ml, GMDTC 3mg/ml - Cisplatin Nephrotoxicity, Cisplatin Adverse Reaction | Phase 1 | Not yet recruiting | Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. | 60 | 2026-10-01 | 2026-09-17 |
| Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients N acetyl cysteine - Cisplatin Adverse Reaction, Cisplatin Nephrotoxicity | Phase 2 | Unknown | Ain Shams University | 60 | 2024-02-01 | 2024-03-07 |
| Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors Lipid profile, Coronary artery assessment, Hormone levels for hypogonadism - Testicular Cancer, Survivorship | Recruiting | Indiana University | 150 | 2022-10-11 | 2026-07-27 | |
| Comparative Study of Different Doses of Magnesium as a Protective Agent in Nephrotoxicity in Cancer Patients cisplatin with hydration magnesium, cisplatin 40 mg/m² - Cisplatin Adverse Reaction | Phase 2 | Completed | Tanta University | 100 | 2022-10-01 | 2026-03-23 |
| Evaluation of the Effect of Genetic Polymorphisms in ERCC1 and OCT2 on the Occurrence and Severity of Cisplatin-induced Nephrotoxicity ERCC1, OCT2 - Cisplatin Adverse Reaction | Unknown | Ain Shams University | 89 | 2022-02-15 | 2022-02-21 | |
| Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity Rosuvastatin 10mg - Cisplatin Adverse Reaction | Phase 2 | Unknown | Cairo University | 65 | 2020-11-17 | 2021-07-28 |
| Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer N Acetylcysteine, Placebo Oral Tablet - Cisplatin Adverse Reaction, Hearing Loss Ototoxic | Not applicable | Completed | Hospital San Juan de Dios, Santiago | 45 | 2015-11-01 | 2018-01-17 |
| Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury Gemigliptin, Placebo, Cisplatin - Cancer, Cisplatin Adverse Reaction | Phase 2 / Phase 3 | Unknown | Seoul National University Bundang Hospital | 182 | 2014-12-01 | 2016-04-20 |
| Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma Silymarin, Placebo, chemotherapy - Upper GI Cancer, Cisplatin Adverse Reaction | Phase 2 / Phase 3 | Completed | Tehran University of Medical Sciences | 30 | 2013-08-01 | 2015-05-13 |
| Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy Placebo, Gabapentin - Vomiting, Cisplatin Adverse Reaction | Phase 3 | Completed | Faculdade de Medicina do ABC | 80 | 2009-01-01 | 2014-03-07 |
Ototoxicity (3) · Coronary Artery Disease (1) · Eunuchism (1) · Gastrointestinal Neoplasms (1) · Lipid Metabolism Disorders (1) · Neoplasms (1) · Peripheral Nervous System Diseases (1) · Testicular Neoplasms (1) · Vomiting (1)
Pathological Conditions, Signs and Symptoms (4) · Chemically-Induced Disorders (3) · Drug-Related Side Effects and Adverse Reactions (3) · Ear Diseases (3) · Otorhinolaryngologic Diseases (3) · Pathologic Processes (3) · Radiation Injuries (3) · Wounds and Injuries (3) · Neoplasms (2) · Neoplasms by Site (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiovascular Diseases (1) · Coronary Disease (1) · Digestive System Diseases (1)
Cisplatin (3) · Acetylcysteine (2) · Docetaxel (1) · Drug Therapy (1) · Fluorouracil (1) · Gabapentin (1) · LC15-0444 (1) · Rosuvastatin Calcium (1) · Silymarin (1) · milk-thistle extract (1)
Ain Shams University (2) · Cairo University (1) · Faculdade de Medicina do ABC (1) · Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. (1) · Hospital San Juan de Dios, Santiago (1) · Indiana University (1) · Seoul National University Bundang Hospital (1) · Tanta University (1) · Tehran University of Medical Sciences (1)
Egypt (4) · Brazil (1) · Chile (1) · China (1) · Iran (1) · South Korea (1) · United States (1)
Auro del Giglio, phD (1) · Aya T Moustafa, BSc (1) · Dalia S Elhelw, PhD (1) · Ki Young Na (1) · Lamia Elwakeel (1) · Loay Kassem, PhD (1) · Mohamed H Solayman, PhD (1) · Noah Richardson, MD (1) · Simin Dashti-Khavidaki, Dr (1)